"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at paclitaxel, cisplatin and gemcitabine for cancer of the urinary system (EORTC 30987)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at adding paclitaxel to cisplatin and gemcitabine chemotherapy for cancer of the bladder,
Sometimes the cancer is more difficult to treat because it has already grown outside the urinary system (locally advanced) or spread somewhere else in the body (metastatic). If this happens, you may have chemotherapy. Cisplatin and gemcitabine are 2 drugs that doctors often use.
In this trial, the researchers wanted to see if adding another drug called paclitaxel helped.
The aim of the trial was to see if having all 3 drugs worked better than just having cisplatin and gemcitabine for locally advanced or metastatic cancer of the urinary system.
Summary of results
Initial results showed that the cancer had shrunk or disappeared in more people who had all 3 drugs than in people who had just 2.
627 patients took part in the trial. Over 3 quarters of them had bladder cancer. Half the people taking part had gemcitabine and cisplatin. Half had gemcitabine, cisplatin and paclitaxel.
With the 2 drug combination, the cancer responded in 46 out of every 100 people treated (46%). In 10% of people, all signs of cancer had disappeared (a
With the 3 drug combination, the cancer responded in 57 out of every 100 people treated (57%). In 15%, all signs of cancer had disappeared (complete response).
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Michael Leahy
Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUK/02/001.